Furthermore, a phase I clinical trial revealed major tumor regression in a group of metastatic melanoma patients treated with radiotherapy and an anti-CTLA-4 antibody (Twyman-Saint Victor et al. 2015). Here, CTLA4 is linked to neoplasm.